Journal for ImmunoTherapy of Cancer (Nov 2023)
652 NT-I7 (efineptakin alfa), a long-acting IL-7, in combination with pembrolizumab improves T cell fitness in heavily pretreated subjects with gastrointestinal tumors
- Cara Haymaker,
- Aung Naing,
- Minal Barve,
- Marya Chaney,
- Se Hwan Yang,
- Siyoung Lee,
- Byung Ha Lee,
- Sara Ferrando-Martinez,
- Hirva Mamdani,
- Richard D Kim,
- Meredith Pelster,
- Mohamed Derbala,
- Jack Goon,
- Samuel Darko,
- Julie Murphy,
- Lauren Gorelik,
- Allison Bierly
Affiliations
- Cara Haymaker
- 1The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Aung Naing
- 10The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Minal Barve
- 3Mary Crowley Cancer Research, Dallas, TX, USA
- Marya Chaney
- 19Merck and Co., Inc, Rahway, NJ, USA
- Se Hwan Yang
- 5NeoImmuneTech, Inc., Rockville, MD, USA
- Siyoung Lee
- 6Geninus Inc., Seoul, Republic of Korea
- Byung Ha Lee
- 5NeoImmuneTech, Inc., Rockville, MD, USA
- Sara Ferrando-Martinez
- 5NeoImmuneTech, Inc., Rockville, MD, USA
- Hirva Mamdani
- 2Barbara Ann Karmanos Cancer Institute/Wayne State University, Detroit, MI, USA
- Richard D Kim
- 8Moffitt Cancer Center, Tampa, FL, USA
- Meredith Pelster
- 4Sarah Cannon Research Institute, Nashville, TN, USA
- Mohamed Derbala
- 1The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Jack Goon
- 5NeoImmuneTech, Inc., Rockville, MD, USA
- Samuel Darko
- 5NeoImmuneTech, Inc., Rockville, MD, USA
- Julie Murphy
- 5NeoImmuneTech, Inc., Rockville, MD, USA
- Lauren Gorelik
- 5NeoImmuneTech, Inc., Rockville, MD, USA
- Allison Bierly
- 5NeoImmuneTech, Inc., Rockville, MD, USA
- DOI
- https://doi.org/10.1136/jitc-2023-SITC2023.0652
- Journal volume & issue
-
Vol. 11,
no. Suppl 1
Abstract
No abstracts available.
